Sentiment Analysis: Understand Your Healthcare Customers

 

Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.

In the context of medicinal products and devices, sentiment can be referred to an adverse event experience but also a positive treatment outcome.

The sentiment can be deducted as final output of a technique that includes the massive collection of some unstructured information from any source selected as relevant and their processing aimed to identify and extract the implicit subjective judgment or evaluation.   

Proof of concept: Roche-GSK competition on melanoma therapy

The main goal of the proof of concept (PoC) is to show the applicability of a sentiment analysis approach to clinical data, in the context of social media monitoring, data analysis and reporting. In order to obtain a sensible quantitative analysis we collected data from different sources. It should be noted that because this is a proof of concept we have planned for a limited data investigation. Therefore, by increasing numbers in a production environment we will gain remarkable quantitative improvements and analysis refinements.

 

Specifications

This proof of concept focuses on sentiment analysis of opinions shared on the Web about two products for the treatment of melanoma marketed by GSK and Roche. Our research involved Roche’s single-agent Zelboraf (vemurafenib) and GSK's combination of Mekinist (Trametinib) and Tafinlar (dabrafenib).

Internal server error